ACADIA Pharmaceuticals Inc. news

   Watch this stock
Showing stories 1 - 10 of about 79   

Articles published

ACAD 30.43 -0.62 (-2.00%)
price chart
Cowen Analyst Likes Intercept Pharmaceuticals, ACADIA Pharmaceuticals And ...
Speaking on CNBC's Fast Money, Ritu Baral of Cowen and Company said that Intercept Pharmaceuticals Inc (NASDAQ: ICPT) is a buy.
Why ACADIA Pharmaceuticals (ACAD) Stock Is Spiking Today
NEW YORK (TheStreet) -- ACADIA Pharmaceuticals (ACAD - Get Report) shares are up 12.9% to $27.07 on Tuesday after the company announced that its Parkinson's disease psychosis treatment NUPLAZID was granted a Breakthrough Therapy designation ...
ACADIA Pharmaceuticals Receives FDA Breakthrough Therapy Designation for ...  MarketWatch
BTD for Acadia's Nuplazid (ACAD)  Seeking Alpha (registration)
Related articles »  
This Is A Good Time To Buy Acadia Pharmaceuticals (ACAD)
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) is in the process of a filing a new drug application (NDA) for Nuplazid (pimavanserin), which is a first-in-class treatment for Parkinson's disease psychosis, or PDP.
Related articles »  
Brokerage Firm Price Target on ACADIA Pharmaceuticals Inc.
Cowen & Company initiates coverage on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Cowen & Company has a Outperform rating on the counter.
CEO of ACADIA Pharmaceuticals Inc. Sells Company Shares  Wall Street Pulse
Wednesday Stocks to Watch: ACADIA Pharmaceuticals Inc , ACE Ltd ...  Winston View
First Week of September 18th Options Trading For Acadia Pharmaceuticals ...
Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available this week, for the September 18th expiration.
ACADIA Pharmaceuticals (ACAD) Is Water-Logged And Getting Wetter Today
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders.
Related articles »  
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO, Nov 25, 2014 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. ACAD, -2.00% a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, ...
Related articles »  
Today's Dead Cat Bounce Stock: ACADIA Pharmaceuticals (ACAD)
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders.
Related articles »  
Biotech Stocks Technical Report - Halozyme Therapeutics, Agenus, Biogen Idec ...
Investor-Edge has initiated coverage on the following equities: Halozyme Therapeutics Inc. HALO Agenus Inc. AGEN Biogen Idec Inc. BIIB ACADIA Pharmaceuticals Inc. ACAD and Peregrine Pharmaceuticals Inc. PPHM Free research report on Halozyme ...
Short Interest of ACADIA Pharmaceuticals Inc. Drops by 3.7%
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has witnessed a colossal drop of 3.7% or 668,269 shares in its short figure. The short interest diminution took it from 18,249,201 on December 15,2014 to 17,580,932 on December 31,2014.
Healthcare Stocks Watch List - Array Biopharma (ARRY), ACADIA ...  Techsonian (press release)
Insider Selling: Michael T. Borer Sells 27973 Shares of ACADIA ...  Dakota Financial News